Abstract: A device for monitoring the access to the cardiovascular system of a patient undergoing an extracorporeal treatment of blood in a machine (1) comprising a treatment device (4) and an extracorporeal circuit (2), comprises: a voltage generator (16) for generating a potential difference between a part of the machine (1) and a first point (B) of a venous branch (8) of the extracorporeal circuit (2), connecting the patient to the treatment device (4); a detector (17) for detecting the value (dV) of a quantity that correlates with the electric current along at least one section (10a; 10b; 10c) of the venous branch (10) between the first point (B) and a venous needle (13) fitted at the end of the venous branch (8) and inserted in the vascular system of the patient (P); calculating means (15) for comparing the detected value (dV) with a reference range (I).

Abstract: The invention provides a control device for the separate collection of blood components in output from a blood centrifugation cell. The control device comprises: a support which comprises a recess for containing a duct; a visible-light emitter with a corresponding receiver, which are arranged on opposite sides with respect to the recess for containing the duct; an infrared-light emitter with a corresponding receiver, which are arranged on opposite sides with respect to the recess for containing the duct; and a processor to detect signals acquired by the two receivers, to calculate a ratio between the values of the signals, and to send signals to the means suitable to selectively send the fluid conveyed by the duct into separate collection bags, the means being able to change the bag in which the fluid is collected.

Abstract: Novel molecules without intramolecular peptidic bonds, able to mimic the RGD peptide, containing ARG-GLY-ASP motif “arginine-glycine-aspartic acid” (that is a potent inhibitor, in vivo and in vitro, of cellular adhesion) In vitro experimentation demonstrated that said molecules are efficient inhibitors of RASMC adhesion, proliferation and migration.

Abstract: A device for monitoring the access to the cardiovascular system of a patient undergoing an extracorporeal treatment of blood in a machine (1) comprising a treatment device (4) and an extracorporeal circuit (2), comprises: a voltage generator (16) for generating a potential difference between a part of the machine (1) and a first point (B) of a venous branch (8) of the extracorporeal circuit (2), connecting the patient to the treatment device (4); a detector (17) for detecting the value (dV) of a quantity that correlates with the electric current along at least one section (10a; 10b; 10c) of the venous branch (10) between the first point (B) and a venous needle (13) fitted at the end of the venous branch (8) and inserted in the vascular system of the patient (P); calculating means (15) for comparing the detected value (dV) with a reference range (T).

Abstract: Novel molecules without intramolecular peptidic bonds, able to mimic the RGD peptide, containing ARG-GLY-ASP motif “arginine-glycine-aspartic acid” (that is a potent inhibitor, in vivo and in vitro, of cellular adhesion) In vitro experimentation demonstrated that said molecules are efficient inhibitors of RASMC adhesion, proliferation and migration.